TSE:TRIL Trillium Therapeutics (TRIL) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free TRIL Stock Alerts Add Compare Share Share Today's Range N/A50-Day RangeC$23.33▼C$23.3352-Week Range N/AVolume60,423 shsAverage Volume166,586 shsMarket CapitalizationC$2.45 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Trillium Therapeutics alerts: Email Address Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Trillium Therapeutics Stock (TSE:TRIL)Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.Read More Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. TRIL Stock News HeadlinesApril 11, 2024 | seekingalpha.comSYRE Spyre Therapeutics, Inc.February 22, 2024 | benzinga.comViking Therapeutics Stock (NASDAQ:VKTX), Analyst Ratings, Price Targets, PredictionsApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.February 21, 2024 | health.usnews.comBlue Cross & Blue Shield of Rhode Island Insurance Company Medicare Advantage Plans with Part DApril 7, 2023 | marketwatch.com2023-2030 Bromodomain Containing Protein 2 Market Size Detailed Report with Sales and Revenue Analysis | Research by Absolute ReportsMarch 23, 2023 | finance.yahoo.comMonte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of DirectorsMarch 13, 2023 | finance.yahoo.comRatio Therapeutics Appoints Dr. Noel Monks as Head of BiologyMarch 13, 2023 | reuters.comFactbox: Pfizer snaps up Seagen for $43 bln as drugmaker extends buying spreeApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.February 24, 2023 | benzinga.comAllogene Therapeutics Stock (NASDAQ:ALLO), Quotes and News SummaryFebruary 23, 2023 | finance.yahoo.comTvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast CancerFebruary 6, 2023 | markets.businessinsider.comViridian Therapeutics Names Scott Myers CEO, Succeeding Jonathan ViolinOctober 26, 2022 | finance.yahoo.comAlex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxietyAugust 5, 2022 | finance.yahoo.comPfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJJuly 29, 2022 | ca.finance.yahoo.comLeukemia Therapeutics Global Market Report 2022July 18, 2022 | thestreet.comTrillium Therapeutics Inc. NewsJune 10, 2022 | finance.yahoo.comRatio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of CancersMay 10, 2022 | chron.comPfizer Pays $11.6 Billion for Drug-Maker in Its Biggest Deal Since 2016May 10, 2022 | finanznachrichten.deBloom Burton & Co. Inc.: Three Finalists Announced for the 2022 Bloom Burton AwardMay 10, 2022 | stockhouse.comThree Finalists Announced for the 2022 Bloom Burton AwardMay 10, 2022 | yahoo.comPfizer to buy migraine drugmaker Biohaven in $11.6-billion dealJanuary 26, 2022 | finance.yahoo.comGenScript ProBio Initiates a CDMO Contract For Next-Generation CD47 Antibody with InnoBation BioDecember 16, 2021 | au.finance.yahoo.comCD47 Targeting Global Therapeutics Market 2021-2035, by Target Disease Indication, Type of Molecule Key Players and Key Geographical RegionsOctober 28, 2021 | finance.yahoo.comTrillium Therapeutics Receives Final Court Order Approving ArrangementOctober 26, 2021 | theglobeandmail.comShareholders of cancer-drug developer Trillium Therapeutics approve takeover by Pfizer Inc.October 26, 2021 | finance.yahoo.comTrillium Securityholders Approve Acquisition by PfizerOctober 13, 2021 | law360.comPfizer Gives Gov't More Time To Study $2.3B Trillium DealSee More Headlines Receive TRIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:TRIL Previous SymbolTSE:SSS CUSIPN/A CIKN/A Webwww.trilliumtherapeutics.com Phone+1-416-5950627FaxN/AEmployees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.27 Current Ratio12.04 Quick Ratio11.54 Sales & Book Value Annual SalesC$43,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow9.77 Book ValueC$2.17 per share Price / BookN/AMiscellaneous Outstanding Shares104,995,000Free FloatN/AMarket CapC$2.45 billion OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Jan Skvarka (Age 54)Pres, CEO & Director Comp: $812.5kMr. James T. Parsons C.A. (Age 56)C.P.A., MAcc, CPA-CA, Chief Financial Officer Comp: $543.38kDr. Robert Uger (Age 50)Chief Scientific Officer Comp: $595.73kDr. Penka Petrova (Age 53)Chief Devel. Officer Comp: $553.53kDr. Ingmar Bruns M.D. (Age 46)Ph.D., Chief Medical Officer Comp: $230kBenjamin LookerGen. CounselDr. Rosemary Harrison (Age 38)Sr. VP of Corp. Devel. & Strategy Dr. Michael G. HillHead of Calgary SiteMs. Kathleen Large (Age 61)Sr. VP - Clinical Operations More ExecutivesKey CompetitorsBELLUS HealthTSE:BLUConcordia InternationalTSE:CXRTilray BrandsTSE:TLRYCronos GroupTSE:CRONdentalcorpTSE:DNTLView All Competitors TRIL Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Canada Goose (GOOS), Moderna (MRNA), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Zoom Video Communications (ZM), Advanced Micro Devices (AMD) and Canadian Natural Resources (CNQ). How do I buy shares of Trillium Therapeutics? Shares of TRIL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:TRIL) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
